[1] CHOI J,JO C,LIM Y S.Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Hepatology,2021,73(2):661-673. [2] THULUVATH P J,TO C,AMJAD W.Role of locoregional therapies in patients with hepatocellular cancer awaiting liver transplantation[J]. Am J Gastroenterol,2021,116(1):57-67. [3] LEE S,KANG T W,SONG K D,et al.Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation[J].Ann Surg,2021,273(3):564-571. [4] DAI Y F,QIANG W J,LIN K Q,et al.An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma[J].Cancer Immunol Immunother,2021,70(4):967-979. [5] LIU X L,LI M G,WANG X H,et al.Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma[J]. Phytomedicine,2019,62:152930. [6] 管晨滔,赵宏,李新庆,等.肝细胞癌患者的基本特征及其生存分析[J] . 中华肿瘤杂志,2017,39(3):231-235. [7] ZHENG R S,QU C F,ZHANG S W,et al.Liver cancer incidence and mortality in China:temporal trends and projections to 2030[J]. Chin J Cancer Res,2018,30(6):571-579. [8] WANG X L,HE Y,MACKOWIAK B,et al.microRNAs as regulators,biomarkers and therapeutic targets in liver diseases[J]. Gut,2021,70(4):784-795. [9] XU J,WU C,CHE X,et al.Circulating microRNAs,miR-21,miR-122,and miR-223,in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog,2011,50(2):136-142. [10] SILAKIT R,LOILOME W,YONGVANIT P,et al.Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients:a prospective prognostic indicator[J].J Hepatobiliary Pancreat Sci,2014,21(12):864-872. [11] MOTAWI T K,SHAKER O G,EL-MARAGHY S A,et al. Serum microRNAs as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma in Egyptian patients[J]. PLoS One,2015,10(9):e0137706. [12] ZUO D,CHEN L W,LIU X Q,et al.Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma[J]. Tumour Biol,2016,37(5):6539-6549. [13] WANG C,HANN H W,YE Z,et al.Prospective evidence of a circulating microRNA signature as a non-invasive marker of hepatocellular carcinoma in HBV patients[J]. Oncotarget,2016. [14] ZHOU J,YU L,GAO X,et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol,2011,29(36):4781-4788. [15] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志, 2017,16(7):635-647. [16] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90. [17] FERLAY J,SHIN H R,BRAY F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917. [18] 侯玉丽,姜菲菲,王颖,等. AFP在早期肝癌诊断中的临床价值研究[J]. 中国现代医学杂志,2018,28(5):92-96. [19] ODENY T A,FARHA N,HILDEBRANDAND H,et al.Association between primary perioperative CEA ratio,tumor site,and overall survival in patients with colorectal cancer[J]. J Clin Med,2020,9(12):3848. [20] MIZUNO H,MIYAKE H,NAGAI H,et al.Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage Ⅱ/Ⅲ colon cancer[J]. Langenbecks Arch Surg,2021,406(6):1987-1997. [21] WANG Y,ZHANG P,YUAN M,et al.Overexpression of miRNA-21 promotes the proliferation and invasion in hepatocellular carcinoma cells via suppressing SMAD7[J].Technol Cancer Res Treat,2019,18:1533033819878686. [22] ZHU W J,YAN Y,ZHANG J W,et al.Effect and mechanism of miR-26a-5p on proliferation and apoptosis of hepatocellular carcinoma cells[J].Cancer Manag Res,2020,12:3013-3022. [23] JIAO Y,XU P,SHI H L,et al.Advances on liver cell-derived exosomes in liver diseases[J].J Cell Mol Med,2021,25(1):15-26. [24] WANG S,YANG Y X,SUN L L,et al.Exosomal microRNAs as liquid biopsy biomarkers in hepatocellular carcinoma[J].Oncotargets Ther,2020,13:2021-2030. |